96 related articles for article (PubMed ID: 9053597)
1. [A new, more expensive agent against ovarian cancer. Worth its price?].
Högberg T; Karlsson G; Ridderheim M; Boman K; Frankendal B; Horvath G; Sorbe B; Strang P; Rosenberg P
Lakartidningen; 1997 Jan; 94(1-2):21-4. PubMed ID: 9053597
[No Abstract] [Full Text] [Related]
2. NICE approves Taxol for ovarian cancer.
Kmietowicz Z
BMJ; 2000 May; 320(7245):1293. PubMed ID: 10807610
[No Abstract] [Full Text] [Related]
3. The pharmacoeconomics of cancer therapies.
Bishop JF; Macarounas-Kirchman K
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
[TBL] [Abstract][Full Text] [Related]
4. Willingness to pay for new chemotherapy for advanced ovarian cancer.
Morris J; Perez D
N Z Med J; 2000 Apr; 113(1108):143-6. PubMed ID: 10872435
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
Messori A; Cecchi M; Becagli P; Trippoli S
Cancer; 1997 Jun; 79(11):2264-6. PubMed ID: 9179077
[No Abstract] [Full Text] [Related]
6. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.
Ortega A; Dranitsaris G; Sturgeon J; Sutherland H; Oza A
Gynecol Oncol; 1997 Sep; 66(3):454-63. PubMed ID: 9299261
[TBL] [Abstract][Full Text] [Related]
7. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
[TBL] [Abstract][Full Text] [Related]
8. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
Elit LM; Gafni A; Levine MN
J Clin Oncol; 1997 Feb; 15(2):632-9. PubMed ID: 9053487
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.
Limwattananon S; Limwattananon C; Maoleekulpairoj S; Soparatanapaisal N
J Med Assoc Thai; 2006 May; 89(5):690-8. PubMed ID: 16756057
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.
McGuire W; Neugut AI; Arikian S; Doyle J; Dezii CM
J Clin Oncol; 1997 Feb; 15(2):640-5. PubMed ID: 9053488
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
Messori A; Trippoli S
Anticancer Drugs; 1998 Nov; 9(10):909-16. PubMed ID: 9890702
[TBL] [Abstract][Full Text] [Related]
12. [Paclitaxel, a new anticancer drug].
Jekunen A; Lehtovirta P; Pyrhönen S
Duodecim; 1994; 110(13):1235-40. PubMed ID: 7497933
[No Abstract] [Full Text] [Related]
13. Paclitaxel in advanced ovarian cancer: too much optimism?
Bulusu VR; Allerton R
Gynecol Oncol; 1997 Aug; 66(2):335-6. PubMed ID: 9264587
[No Abstract] [Full Text] [Related]
14. [Second-line chemotherapy for ovarian cancer: the potential of Taxol].
Maksimov SIa
Vopr Onkol; 2002; 48(1):99-101. PubMed ID: 12101579
[No Abstract] [Full Text] [Related]
15. [Chemotherapy of ovarian and breast cancer with Taxol].
Dtsch Med Wochenschr; 1996 Dec; 121(50 Suppl):1-12. PubMed ID: 9022362
[No Abstract] [Full Text] [Related]
16. [The role of paclitaxel in the first line treatment of cancer of the ovary?].
Slimane K
Bull Cancer; 2003 Mar; 90(3):202-3. PubMed ID: 12803089
[No Abstract] [Full Text] [Related]
17. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
18. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
Dranitsaris G; Elia-Pacitti J; Cottrell W
Pharmacoeconomics; 2004; 22(6):375-87. PubMed ID: 15099123
[TBL] [Abstract][Full Text] [Related]
19. [Taxanes--a new generation of cytostatic drugs].
Diehl V; Steinmetz T
Med Klin (Munich); 1993 Nov; 88 Suppl 2():3. PubMed ID: 7907773
[No Abstract] [Full Text] [Related]
20. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
